Fresenius Medical Care : Q3 due 1 November – Headwinds to continue
>Labour shortage blocks new patient growth - Q3 2022 revenues of € 5,066m (+14.1% y-o-y, 1% ahead of consensus) should profit primarily from a forex tailwind of 11.4 percentage points. Organic growth of only 1.8% is impacted by a decline of -0.8% in North America on the back of a labour shortage. We calculate an external growth contribution of 80bp. The shortage of nurses to operate dialysis services was the primary reason for the guidance cut in July and we expect on...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.